Royalty Pharma Sub-Manager, LLC Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0002081668
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 4 positions · Total reported value $171.31M · Top-10 concentration 100.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 0.0% · 0 new · 0 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q4 2025 13F filing, Royalty Pharma Sub-Manager, LLC disclosed 4 equity positions with a combined reported value of $171.31M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / Buy & Hold.
The largest disclosed positions as of Q4 2025 were CYTK ($62.29M), ZBIO ($45.86M), BHVN ($33.15M). By sector, the heaviest allocations are Health Care 100.0%.
Versus the prior quarter, Royalty Pharma Sub-Manager, LLC opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions.
The largest new positions opened in Q4 2025 were CYTK ($62.29M), ZBIO ($45.86M), BHVN ($33.15M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest Royalty Pharma Sub-Manager, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Royalty Pharma Sub-Manager, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 4 US equity positions with a combined value of $241.92M. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-132133 (status: Approved), registered 2025-03-07
- Regulatory AUM (Form ADV): $19.64B as of 2026-05-04
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds
Portfolio Structure
- 4 positions · $241.92M reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: CYTK (CYTOKINETICS INC) at 34.5%
- Average position size: $60.48M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 1 new, 1 exited
- 3 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
FAQ
What did Royalty Pharma Sub-Manager, LLC buy in 2025-Q4?
In its 2025-Q4 13F filing, Royalty Pharma Sub-Manager, LLC reported 4 equity positions worth $171.31M in aggregate; its largest disclosed positions were CYTK ($62.29M), ZBIO ($45.86M), BHVN ($33.15M).
How large is Royalty Pharma Sub-Manager, LLC's portfolio?
Royalty Pharma Sub-Manager, LLC reported $171.31M of long equity holdings across 4 positions as of 2025-Q4. Top-10 holdings account for 100.0% of reported value.
What is Royalty Pharma Sub-Manager, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.